Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer
1996

Cisplatin and Etoposide for Colorectal Cancer

Sample size: 14 publication Evidence: low

Author Information

Author(s): AST Planting, MEL van der Burg, MJ van den Bent, M de Boer-Dennert, G Stoter, J Verweijl

Primary Institution: Rotterdam Cancer Institute/Daniel den Hoed Kliniek

Hypothesis

Can a combination of high-dose cisplatin and oral etoposide be an effective first-line treatment for metastatic colorectal cancer?

Conclusion

The combination of cisplatin and oral etoposide showed minimal activity in treating metastatic colorectal cancer.

Supporting Evidence

  • A partial response was observed in two patients with liver metastases.
  • Five patients had stable disease.
  • Toxicity included anaemia, leucocytopenia, nausea, and vomiting.

Takeaway

Doctors tried a new medicine combination to help people with a type of cancer, but it didn't work very well.

Methodology

Patients received high-dose cisplatin and oral etoposide, with evaluations of response and toxicity.

Limitations

The study had a small sample size and did not show significant benefits from the treatment.

Participant Demographics

14 patients, mostly male, with a median age of 53 years.

Statistical Information

Confidence Interval

95% CI 2-42%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication